The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer

Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy

(2012) Dariusz Pytel et al.   Anti-Cancer Agents in Medicinal Chemistry

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

(2011) Richard A Adams et al.   LANCET ONCOLOGY

Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a phase III trial: final results and geographical analysis

(2010) D Cella et al.   BRITISH JOURNAL OF CANCER

Sunitinib rechallenge in metastatic renal cell carcinoma patients

(2010) Ivan N. Zama et al.   CANCER

Toxicity associated with the long-term use of targeted therapies in patients with advanced renal cell carcinoma

(2009) Dale R Shepard et al.   Expert Review of Anticancer Therapy

A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety

(2009) H. Uemura et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

(2009) Benoist Chibaudel et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY

It's not just what you say, it's also how you say it: Opening the ‘black box’ of informed consent appointments in randomised controlled trials

(2009) Julia Wade et al.   SOCIAL SCIENCE & MEDICINE

Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis

(2008) Manfred Johannsen et al.   EUROPEAN UROLOGY

Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial

(2008) David Cella et al.   JOURNAL OF CLINICAL ONCOLOGY